Adlai Nortye Ltd. (NASDAQ:ANL – Get Free Report) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 6,800 shares, an increase of 112.5% from the December 31st total of 3,200 shares. Based on an average daily volume of 16,400 shares, the short-interest ratio is presently 0.4 days.
Adlai Nortye Price Performance
Shares of NASDAQ ANL opened at $2.08 on Wednesday. The stock’s 50-day simple moving average is $2.22 and its 200-day simple moving average is $2.49. Adlai Nortye has a fifty-two week low of $1.85 and a fifty-two week high of $17.48.
Analyst Ratings Changes
Separately, HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Adlai Nortye in a report on Monday, November 11th.
Adlai Nortye Company Profile
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Featured Stories
- Five stocks we like better than Adlai Nortye
- How to Calculate Inflation Rate
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- What Are Trending Stocks? Trending Stocks Explained
- What Does the Future Hold for Eli Lilly?
- 3 Warren Buffett Stocks to Buy Now
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
